Further validation for Biocellvia’s digital image analysis in new scientific article published by Gustave Roussy

Biocellvia will take part to BIO18 : the 2018 BIO International Conference
Biocellvia will be at BIO18
avril 23, 2018
Biocellvia accelerates its R&D in oncology : lung cancer and breast cancer
Biocellvia accelerates its R&D in oncology
mai 23, 2018
Show all

Further validation for Biocellvia’s digital image analysis in new scientific article published by Gustave Roussy

Further validation for Biocellvia’s digital image analysis in new scientific article published by Gustave Roussy in collaboration with Biocellvia

Biocellvia is proud to announce its acknowledgement in the scientific article published in the European Respiratory Journal in April, in collaboration with the team at Gustave Roussy, the premier European Cancer Center.

In this paper, the authors set out to characterize infiltrating pulmonary macrophages in radiation-induced lung fibrosis (RIF), both from human lung biopsies from patients who have received chest radiotherapy, and also in a murine preclinical model after irradiation. One of the interesting findings of the paper is that the CSF1/CSFIR pathway emerged as a potential target for inhibiting RIF, raising exciting implications in future drug discovery research for pulmonary fibrosis patients.

Scientific article : Gustave Roussy collaboration with a breakthrough innovation 

Biocellvia deployed its automated histological image analysis program and contributed to the results by generating valuable quantitative data on the level of lung fibrosis observed in parenchymal tissues, based on H&E stained images.

Biocellvia’s machine learning based software was built and wholly developed by specialist biologist and software developer teams dedicated to the project within Biocellvia. The algorithm and program are proprietary and patented, and is entirely unique in the industry, because it allows the complete automatic quantification without any manual annotation.

For pulmonary fibrosis, Biocellvia’s program can automatically delineate and exclude the unwanted bronchi and vessels, so that the quantification is done solely on parenchymal tissues. Therefore, the results are much more relevant and biologically meaningful. The program assess the severity of fibrosis by transforming each native RGB pixel values into individual density values, and fibrotic foci in the parenchymal tissues are represented by the highest density values.

Important to note that Biocellvia’s advanced program can in fact generate multiple morphological parameters in additional to parenchymal tissue density. The program can calculate six morphometric parameters from just Picrosirius-red stained sections: i ) parenchymal tissue density; ii) percentage of fibrotic foci; iii) collagen content; iv) number of airspaces per mm2 of parenchymal tissue; v) airspace diameter; vi) airspace density.

Escalating success and recognition for Biocellvia, the intelligent image analysis expert

“This new scientific article undoubtedly is another exciting achievement and validation from a highly distinguished institution in the scientific and medical community.” says, Prof. Yvon Julé, the founder and CSO of Biocellvia. The company’s creation was based on Prof. Yvon Julé’s decade of experience in both academia and industry in specialized digital image analysis. His previous collaboration with Boehringer Ingelheim also resulted in last year’s publication in PLoS One (http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0170561). Prof. Yvon Julé is currently working on a number of industry and academic collaborations, including with the preeminent Ivy League universities in the United States. These projects are aimed at either applying Biocellvia’s validated program suite in respiratory diseases in the preclinical setting to test interesting new theories for publication, or to develop novel programs for other pathologies such as liver diseases, oncology, and neurodegenerative diseases.

Biocellvia continues to commit its resources to research and development, with the aspiration of leveraging its breakthrough technology to accelerate the drug discovery process in the preclinical phase, and bring valuable medical treatments for difficult diseases to patients much faster and at a more affordable cost.

Biocellvia is thankful for the acknowledgement in this new scientific article published by Gustave Roussy, and is equally thrilled to be the central force in the digital revolution in histology and pathology.

Laisser un commentaire

Votre adresse de messagerie ne sera pas publiée. Les champs obligatoires sont indiqués avec *